Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients

  • Wang, Wen-Tao (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University) ;
  • Li, Yin (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University) ;
  • Ma, Jie (Department of Molecular Pathology, the Affiliated Tumor Hospital of Zhengzhou University) ;
  • Chen, Xiao-Bing (Department of Oncology, the Affiliated Tumor Hospital of Zhengzhou University) ;
  • Qin, Jian-Jun (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University)
  • Published : 2014.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) define specific molecular subsets of lung adenocarcinomas with distinct clinical features. Our purpose was to analyze clinical features and prognostic value of EGFR gene mutations and the EML4-ALK fusion gene in lung adenocarcinoma. Patients and Methods: EGFR gene mutations and the EML4-ALK fusion gene were detected in 92 lung adenocarcinoma patients in China. Tumor marker levels before first treatment were measured by electrochemiluminescence immunoassay. Results: EGFR mutations were found in 40.2% (37/92) of lung adenocarcinoma patients, being identified at high frequencies in never-smokers (48.3% vs. 26.5% in smokers; P=0.040) and in patients with abnormal serum carcinoembryonic antigen (CEA) levels before the initial treatment (58.3% vs. 28.6%, P=0.004). Multivariate analysis revealed that a higher serum CEA level before the initial treatment was independently associated with EGFR gene mutations (95%CI: 1.476~11.343, P=0.007). We also identified 8 patients who harbored the EML4-ALK fusion gene (8.7%, 8/92). In concordance with previous reports, younger age was a clinical feature for these (P=0.008). Seven of the positive cases were never smokers, and no coexistence with EGFR mutation was discovered. In addition, the frequency of the EML4-ALK fusion gene among patients with a serum CEA concentration below 5ng/ml seemed to be higher than patients with a concentration over 5ng/ml (P=0.021). No significant difference was observed for time to progression and overall survival between EML4-ALK-positive group and EML4-ALK-negative group or between patients with and without an EGFR mutation. Conclusions: The serum CEA level before the initial treatment may be helpful in screening population for EGFR mutations or EML4-ALK fusion gene presence in lung adenocarcinoma patients.

Keywords

References

  1. Aydiner A, Yildiz I and Seyidova A (2013). Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status. Asian Pac J Cancer Prev, 14, 3255-61. https://doi.org/10.7314/APJCP.2013.14.5.3255
  2. Benchimol S, Fuks A, Jothy S, et al (1989). Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell, 57, 327-34. https://doi.org/10.1016/0092-8674(89)90970-7
  3. Bergman B, Brezicka FT, Engstrom CP, et al (1993). Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer, 29A, 198-202.
  4. Blumenthal RD, Hansen HJ and Goldenberg DM (2005). Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res, 65, 8809-17. https://doi.org/10.1158/0008-5472.CAN-05-0420
  5. Choi YL, Sun JM, Cho J, et al (2013). EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One, 8, e56011. https://doi.org/10.1371/journal.pone.0056011
  6. Cook MB, Dawsey SM, Freedman ND, et al (2009). Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev, 18, 1174-82. https://doi.org/10.1158/1055-9965.EPI-08-1118
  7. Dearden S, Stevens J, Wu YL, et al (2013). Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol, 24, 2371-6. https://doi.org/10.1093/annonc/mdt205
  8. Fukuoka M, Wu YL, Thongprasert S, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 29, 2866-74. https://doi.org/10.1200/JCO.2010.33.4235
  9. Gahr S, Stoehr R, Geissinger E, et al (2013). EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer, 109, 1821-8. https://doi.org/10.1038/bjc.2013.511
  10. Herbst RS (2004). Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys, 59, 21-6. https://doi.org/10.1016/j.ijrobp.2003.10.027
  11. Horinouchi H, Sekine I, Sumi M, et al (2012). Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. Cancer Sci, 103, 756-9. https://doi.org/10.1111/j.1349-7006.2012.02217.x
  12. Ishiguro F, Fukui T, Mori S, et al (2010). Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg, 16, 242-7.
  13. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  14. Li Y, Li Y, Yang T, et al (2013). Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One, 8, e52093. https://doi.org/10.1371/journal.pone.0052093
  15. Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8. https://doi.org/10.1056/NEJMoa0909530
  16. Miyanaga A, Shimizu K, Noro R, et al (2013). Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer, 13, 262. https://doi.org/10.1186/1471-2407-13-262
  17. Nagai Y, Miyazawa H, Huqun, et al (2005). Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res, 65, 7276-82. https://doi.org/10.1158/0008-5472.CAN-05-0331
  18. Okamoto T, Nakamura T, Ikeda J, et al (2005). Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer, 41, 1286-90. https://doi.org/10.1016/j.ejca.2005.03.011
  19. Ordonez C, Screaton RA, Ilantzis C, et al (2000). Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res, 60, 3419-24.
  20. Ozgul MA, G KRL, Seyhan EC, et al (2013). The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer. Multidiscip Respir Med, 8, 69. https://doi.org/10.1186/2049-6958-8-69
  21. Planchard D (2013). Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol, 8, 3-14. https://doi.org/10.1007/s11523-013-0263-z
  22. Qin HF, Qu LL, Liu H, et al (2013). Serum CEA level change and its significance before and after gefitinib therapy on patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4205-8. https://doi.org/10.7314/APJCP.2013.14.7.4205
  23. Ravindranath N, Wion D, Brachet P, et al (2001). Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl, 22, 432-43.
  24. Scaltriti M and Baselga J (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 12, 5268-72. https://doi.org/10.1158/1078-0432.CCR-05-1554
  25. Screaton RA, Penn LZ and Stanners CP (1997). Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol, 137, 939-52. https://doi.org/10.1083/jcb.137.4.939
  26. Shaw AT, Kim DW, Nakagawa K, et al (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368, 2385-94. https://doi.org/10.1056/NEJMoa1214886
  27. Shaw AT, Yeap BY, Mino-Kenudson M, et al (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 27, 4247-53. https://doi.org/10.1200/JCO.2009.22.6993
  28. Shoji F, Yoshino I, Yano T, et al (2007). Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer, 110, 2793-8. https://doi.org/10.1002/cncr.23101
  29. Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6. https://doi.org/10.1038/nature05945
  30. Usuda K, Sagawa M, Motono N, et al (2014). Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev, 15, 657-62. https://doi.org/10.7314/APJCP.2014.15.2.657
  31. Wu YC, Chang IC, Wang CL, et al (2013). Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One, 8, e70839. https://doi.org/10.1371/journal.pone.0070839
  32. Yatabe Y and Mitsudomi T (2007). Epidermal growth factor receptor mutations in lung cancers. Pathol Int, 57, 233-44. https://doi.org/10.1111/j.1440-1827.2007.02098.x
  33. Zhang Y, Wang Q, Han ZG, et al (2013). Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups. Asian Pac J Cancer Prev, 14, 2879-83. https://doi.org/10.7314/APJCP.2013.14.5.2879

Cited by

  1. Correlation between Serum Carcinoembryonic Antigen Level and Histologic Subtype in Resected Lung Adenocarcinoma vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3857
  2. Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patients vol.7, pp.1, 2016, https://doi.org/10.1111/1759-7714.12265
  3. Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vol.94, pp.50, 2015, https://doi.org/10.1097/MD.0000000000002239